Statement: in the primary clinical trial, neutropenia was observed in numerous patients across both cohorts
Primary_evidence: Adverse Events 1:   Total: 3/39 (7.69%)   Neutropenia  1/39 (2.56%)   Bilateral Pulmonary Thromboembolism  0/39 (0.00%)   Fever  1/39 (2.56%)   Empyema associated with a permanent thoracic catheter  1/39 (2.56%) Adverse Events 2:   Total: 3/21 (14.29%)   Neutropenia  1/21 (4.76%)   Bilateral Pulmonary Thromboembolism  1/21 (4.76%)   Fever  1/21 (4.76%)   Empyema associated with a permanent thoracic catheter  0/21 (0.00%)